At the news
? BULLISHIMPACT 7/10 8-K filed Jul 14, 2026 at 08:30 ET
Syndax held an R&D event unveiling two new pipeline assets: SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. The company also highlighted upcoming Phase 2 data readouts for axatilimab in IPF (4Q26) and axatilimab + ruxolitinib in cGVHD (4Q26), and reiterated that Revuforj and Niktimvo are annualizing at ~$200M combined as of 1Q26. No financial results were reported; the filing is a strategic pipeline update.
- Unveiled SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC; IND submission expected by YE 2026, Phase 1 in 2027.
- Unveiled SNDX-62122, a next-generation menin inhibitor for myelofibrosis; IND and Phase 1 expected in 2027.
- Phase 1/2 proof-of-principle trial of revumenib in myelofibrosis expected to initiate in 4Q26 with initial data in 2H27.
- Phase 2 MAXPIRe trial of axatilimab in IPF on track for topline data in 4Q26.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access